A Phase 2 interventional study of Infigratinib 0.016 mg/kg and Infigratinib 0.032 mg/kg in Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Completed at 19 sites in 6 countries. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-10-22.
Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Achondroplasia with a site in United Kingdom — 7 open to participants now, 13 under way, 3 of them phase 3. Achondroplasia · United Kingdom.
Among the 22 studies in Achondroplasia with a site in United Kingdom, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2020, is one of 12 in phase 2, and was the 11th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →7 of the 22 studies in Achondroplasia with a site in United Kingdom are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United Kingdom, United States, Australia and 6 more countries
Ages 2–17
SYSNAV · Sites in United Kingdom, Belgium, France
Ages 2–65
QED Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 0 yrs–32 mo
Tyra Biosciences, Inc · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 3–10
Ascendis Pharma A/S · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 0–2
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 3 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 14 · Phase 3 5
First in 2012; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 77 across the 17 interventional studies, 271 across the 5 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 7 most frequent:
This study is registered under QED Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, a BridgeBio company is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
BridgeBio has 5 studies filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
1 of the studies in Achondroplasia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06732895Ascendis Pharma A/SA Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Achondroplasia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation: Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
Drug: Infigratinib 0.016 mg/kg
Dose Escalation and PK substudy: Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
Drug: Infigratinib 0.032 mg/kg
Dose Escalation and PK substudy: Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
Drug: Infigratinib 0.064 mg/kg
Dose Escalation and PK substudy: Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
Drug: Infigratinib 0.128 mg/kg
Dose Escalation and PK substudy: Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months. Dose Expansion: Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose.
Drug: Infigratinib 0.25 mg/kg
Drug page: Infigratinib
Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Drug page: Infigratinib
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Drug page: Infigratinib
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Drug page: Infigratinib
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Drug page: Infigratinib
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuation
Time frame: Up to 18 months
Change from baseline in annualized height velocity
Time frame: Up to 18 months
PK parameters of infigratinib (Cmax- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (Clast- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (Tmax- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (AUC24- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (T1/2- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (AUCinf- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (CL/F- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (Vz/F- PK substudy only)
Time frame: 21 days
PK parameters of infigratinib (Racc- PK substudy only)
Time frame: 21 days
Incidence of adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability
Time frame: Up to 18 months
Absolute height velocity (annualized to cm/year), expressed numerically and as Z-score in relation to ACH and non-ACH tables
Time frame: Up to 18 months
Absolute and change from baseline in weight (kg)
Time frame: Up to 18 months
Absolute and change from baseline in sitting height (cm)
Time frame: Up to 18 months
Absolute and change from baseline in head circumference (cm)
Time frame: Up to 18 months
Absolute and change from baseline in upper and lower arm length (cm)
Time frame: Up to 18 months
Absolute and change from baseline in thigh length (cm)
Time frame: Up to 18 months
Absolute and change from baseline in knee height (cm)
Time frame: Up to 18 months
Absolute and change from baseline in arm span (cm)
Time frame: Up to 18 months
Pharmacokinetic profile of infigratinib by assessment of maximum concentration (Cmax)
Time frame: Up to 18 months
Pharmacokinetic profile of infigratinib by assessment of time-to-maximum concentration (Tmax)
Time frame: Up to 18 months
Changes in pharmacodynamic parameters by assessing collagen X marker
Time frame: Up to 18 months
Ran from Mar 2020 to primary completion in Oct 2024, 55 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
QED Therapeutics, a BridgeBio company →